Phio director buys 12,000 shares at $1.03

A Phio Pharmaceuticals director bought 12,000 PHIO shares, raising total direct and RSU-linked holdings to 57,651 shares.

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. (PHIO) director Patricia A. Bradford purchased common stock on September 15, 2026. She bought 12,000 shares of common stock at $1.03 per share in an open-market or private transaction, increasing her direct holdings to 57,651 shares, which includes shares underlying unvested restricted stock units.

No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 12,000 shares

Net Buy 1 txn

Insider BRADFORD PATRICIA A

Role Director

Bought 12,000 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $.0001 par value F1	12,000	$1.03	$12K

Holdings After Transaction: Common Stock, $.0001 par value — 57,651 shares (Direct)

Footnotes (1)

1. F1. Includes shares of common stock underlying unvested restricted stock units.

Key Figures

Shares purchased: 12,000 shares Purchase price per share: $1.03 per share Shares held after transaction: 57,651 shares +1 more

4 metrics

Shares purchased 12,000 shares Common stock bought by director on September 15, 2026

Purchase price per share $1.03 per share Price paid for PHIO common stock on September 15, 2026

Shares held after transaction 57,651 shares Director’s direct holdings after the purchase, including unvested RSUs

Net buy shares 12,000 shares Net change in Bradford’s reported PHIO non-derivative position

Key Terms

restricted stock units, Rule 10b5-1 trading plan, open market or private transaction

3 terms

restricted stock units financial

"Includes shares of common stock underlying unvested restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 trading plan regulatory

"No Rule 10b5-1 trading plan is reported for this transaction."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"Purchase in open market or private transaction at $1.03 per share."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PHIO disclose for Patricia A. Bradford?

Phio Pharmaceuticals disclosed that director Patricia A. Bradford purchased 12,000 shares of common stock on September 15, 2026 in an open-market or private transaction at $1.03 per share.

How many PHIO shares does Patricia A. Bradford hold after this transaction?

After the reported purchase, Patricia A. Bradford holds 57,651 shares of Phio Pharmaceuticals common stock, including shares underlying unvested restricted stock units as disclosed in the footnote.

Was Patricia A. Bradford’s PHIO share purchase under a Rule 10b5-1 plan?

No. The filing indicates the Rule 10b5-1 checkbox is not selected, so no Rule 10b5-1 trading plan is reported for this September 15, 2026 purchase.

What price did Patricia A. Bradford pay for PHIO shares in this Form 4?

She purchased the Phio Pharmaceuticals common stock at $1.03 per share for the 12,000 shares reported, characterized as a purchase in an open market or private transaction.

What type of security did Patricia A. Bradford acquire in PHIO?

She acquired Common Stock, $.0001 par value of Phio Pharmaceuticals, with the transaction classified as a non-derivative open-market or private purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:01 PM Accepted by SEC EDGAR 09/16/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRADFORD PATRICIA A

(Last) (First) (Middle)

C/O PHIO PARMACEUTICALS CORP

411 SWEDELAND RD., STE 23-1080

(Street)

KING OF PRUSSIA PENNSYLVANIA 19406

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.0001 par value	09/15/2026		P		12,000	A	$1.03	57,651(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes shares of common stock underlying unvested restricted stock units.

	/s/ Lisa C. Carson, Attorney-in-fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)